The Simplified Mantle-Cell Lymphoma International Prognostic Index predicts overall survival but not progression-free survival in patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide +/- rituximab: results of a randomized phase II trial

Leuk Lymphoma. 2009 Oct;50(10):1709-11. doi: 10.1080/10428190903186494.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Comparative Study
  • Letter
  • Randomized Controlled Trial
  • Validation Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / administration & dosage
  • Disease-Free Survival
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Lymphoma, Mantle-Cell / drug therapy
  • Lymphoma, Mantle-Cell / mortality*
  • Male
  • Middle Aged
  • Prognosis
  • Rituximab
  • Severity of Illness Index*
  • Survival
  • Treatment Outcome
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
  • Cyclophosphamide
  • Vidarabine
  • fludarabine